181 related articles for article (PubMed ID: 11350910)
1. Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo.
Christ O; Matzku S; Burger C; Zöller M
Clin Cancer Res; 2001 May; 7(5):1385-97. PubMed ID: 11350910
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy.
Christ O; Seiter S; Matzku S; Burger C; Zöller M
Clin Cancer Res; 2001 Apr; 7(4):985-98. PubMed ID: 11309350
[TBL] [Abstract][Full Text] [Related]
3. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
4. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
5. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
6. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
[TBL] [Abstract][Full Text] [Related]
7. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
Cao X; Wang Q; Ju DW; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
[TBL] [Abstract][Full Text] [Related]
8. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
9. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
[TBL] [Abstract][Full Text] [Related]
10. [Induction of lymphokine activated killer (LAK) and prolongation of its activity by intrasplenic injection of interleukin 2 (IL-2) in combination with tumor necrosis factor (TNF)].
Nakajima I; Okuno K; Ohnishi H; Shilayama Y; Nakamura T; Hirohata T; Yasutomi M
Nihon Geka Gakkai Zasshi; 1990 Oct; 91(10):1548-53. PubMed ID: 2263237
[TBL] [Abstract][Full Text] [Related]
11. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
12. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
14. Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors.
Lovgren TR; Tarantolo SR; Evans C; Kuszynski CA; Joshi SS
In Vivo; 2002; 16(6):541-50. PubMed ID: 12494899
[TBL] [Abstract][Full Text] [Related]
15. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
Zhang W; Yang H; Wang Z; Jim X
Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
[TBL] [Abstract][Full Text] [Related]
16. Effect of Thuja occidentalis and its polysaccharide on cell-mediated immune responses and cytokine levels of metastatic tumor-bearing animals.
Sunila ES; Hamsa TP; Kuttan G
Pharm Biol; 2011 Oct; 49(10):1065-73. PubMed ID: 21591821
[TBL] [Abstract][Full Text] [Related]
17. The SCID mouse reaction to human peripheral blood mononuclear leukocyte engraftment. Neutrophil recruitment induced expression of a wide spectrum of murine cytokines and mouse leukopoiesis, including thymic differentiation.
Santini SM; Rizza P; Logozzi MA; Sestili P; Gherardi G; Lande R; Lapenta C; Belardelli F; Fais S
Transplantation; 1995 Dec; 60(11):1306-14. PubMed ID: 8525526
[TBL] [Abstract][Full Text] [Related]
18. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
